Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004055502 | SCV002681777 | uncertain significance | not specified | 2022-09-04 | criteria provided, single submitter | clinical testing | The p.R272Q variant (also known as c.815G>A), located in coding exon 1 of the PALLD gene, results from a G to A substitution at nucleotide position 815. The arginine at codon 272 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005025809 | SCV005657686 | uncertain significance | Pancreatic cancer, susceptibility to, 1 | 2024-03-18 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003933769 | SCV004763049 | likely benign | PALLD-related disorder | 2020-07-03 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |